- recruitingPHASE3
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
This study looks at adding a new medicine, revumenib, to standard chemotherapy for people with a specific type of newly diagnosed acute myeloid leukaemia (AML) with a particular gene change (NPM1 mutation). It aims to see if this combination works better and is safe.
Australia · Georgia · Germany - recruitingPHASE1
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
This study looks at a new drug, SNDX-5613, combined with standard chemotherapy for a type of blood cancer called Acute Myeloid Leukemia (AML). It aims to see how safe and effective this new combination is for people whose AML has specific genetic changes.
United States · Australia · Canada